AGGX

AngioGenex, Inc. (AngioGenex) is a development-stage company. The Company is a biopharmaceutical company focused on the manufacturing of products for the treatment, diagnosis and prognosis of cancer. The Company focuses to develop orally active anti-cancer drugs that act by modulating the action of the inhibitor of differentiation (Id) proteins, measurement of Id proteins in tumors and blood to create products for the diagnosis and prognosis of cancer and generating proof-of-concept data in relevant preclinical models to establish that modulation of Id genes and proteins is useful to treat non-oncologic diseases in which a surplus or deficit in the growth of blood vessels is an important part of the underlying pathology.